Free Lesson Preview
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out β the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Clinical Research Coordinator
Full course Β· Safety Reporting and Pharmacovigilance for CRCs
Free Lesson Preview
The full CRC track covers 8 courses from study start-up to close-out β the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Document concomitant medications that support causality assessment, cross-reference AE and medication records, and handle complex scenarios including rescue medications and self-administered OTC therapies.
A participant in a Phase II oncology trial develops Grade 2 nausea on Study Day 8. The investigator prescribes ondansetron 8 mg twice daily. Three days later, the participant mentions -- almost as an afterthought during a telephone contact -- that she also started taking omeprazole 20 mg daily on her own, "just in case the nausea was from acid." By Study Day 14, the nausea has resolved, but the participant now reports persistent headaches that began around Study Day 11.
The investigator needs to assess causality for the headache. Was it caused by the study drug? By the ondansetron? By the omeprazole the participant started without telling anyone? By some interaction between all three? The answer depends entirely on the completeness of the concomitant medication record. If the coordinator documented only the ondansetron -- the medication the investigator prescribed -- the omeprazole is invisible to the safety analysis. The headache appears to have no pharmacological explanation other than the study drug. But headache is a known side effect of omeprazole. And headache is a known side effect of ondansetron. Without the complete medication picture, the causality assessment is being made with missing evidence, and it may be wrong.
This is not a hypothetical. I have seen this exact pattern -- participants self-medicating, coordinators documenting only prescribed treatments, and investigators making causality judgments on incomplete data -- more times than I care to count. Concomitant medication documentation in the context of safety reporting is not a clerical task. It is an evidentiary task. Every medication a participant takes during an adverse event becomes a variable in the causality equation, and a variable that is not documented is a variable that cannot be analyzed.
Progress saves itself β finish reading and this lesson completes